Reviews Enfuvirtide


No reviews yet.

Fuzeon Drug Description
FUZEON®
(enfuvirtide) for Injection
DRUG DESCRIPTION



What are the possible side effects of enfuvirtide (Fuzeon)?

Get emergency medical help if you have any of these signs of an allergic reaction: skin rash or hives; fever, chills; nausea, vomiting; difficulty breathing; feeling light-headed or fainting; swelling of your face, lips, tongue, or throat.
Stop using enfuvirtide and call your doctor at once if you have any of these serious side effects:

cough with fever, chest congestion, and shortness of breath;
signs of a new infection, such as fever or chills, cough, or flu symptoms.
...
Read All Potential Side Effects for Fuzeon »




FUZEON (enfuvirtide) is an inhibitor of the fusion of HIV-1 with CD4 cells.
Enfuvirtide is a linear 36-amino acid synthetic peptide with the N-terminus
acetylated and the C-terminus is a carboxamide. It is composed of naturally
occurring L-amino acid residues.
Enfuvirtide is a white to off-white amorphous solid. It has negligible solubility
in pure water and the solubility increases in aqueous buffers (pH 7.5) to 85-142
g/100 mL. The empirical formula of enfuvirtide is C204H301N51O64,
and the molecular weight is 4492. It has the following primary amino acid sequence:
CH3CO-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-LeuLeu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2
and the following structural formula:








The drug product, FUZEON (enfuvirtide) for Injection, is a white to off-white,
sterile, lyophilized powder. Each single-use vial contains 108 mg of enfuvirtide
for the delivery of 90 mg. Prior to subcutaneous administration, the contents
of the vial are reconstituted with 1.1 mL of Sterile Water for Injection giving
a volume of approximately 1.2 mL to provide the delivery of 1 mL of the solution.
Each 1 mL of the reconstituted solution contains approximately 90 mg of enfuvirtide
with approximate amounts of the following excipients: 22.55 mg of mannitol,
2.39 mg of sodium carbonate (anhydrous), and sodium hydroxide and hydrochloric
acid for pH adjustment as needed. The reconstituted solution has an approximate
pH of 9.0.Last reviewed on RxList: 1/15/2010




Fuzeon Drug Description
FUZEON®
(enfuvirtide) for Injection
DRUG DESCRIPTION



What are the possible side effects of enfuvirtide (Fuzeon)?

Get emergency medical help if you have any of these signs of an allergic reaction: skin rash or hives; fever, chills; nausea, vomiting; difficulty breathing; feeling light-headed or fainting; swelling of your face, lips, tongue, or throat.
Stop using enfuvirtide and call your doctor at once if you have any of these serious side effects:

cough with fever, chest congestion, and shortness of breath;
signs of a new infection, such as fever or chills, cough, or flu symptoms.
...
Read All Potential Side Effects for Fuzeon »




FUZEON (enfuvirtide) is an inhibitor of the fusion of HIV-1 with CD4 cells.
Enfuvirtide is a linear 36-amino acid synthetic peptide with the N-terminus
acetylated and the C-terminus is a carboxamide. It is composed of naturally
occurring L-amino acid residues.
Enfuvirtide is a white to off-white amorphous solid. It has negligible solubility
in pure water and the solubility increases in aqueous buffers (pH 7.5) to 85-142
g/100 mL. The empirical formula of enfuvirtide is C204H301N51O64,
and the molecular weight is 4492. It has the following primary amino acid sequence:
CH3CO-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-LeuLeu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2
and the following structural formula:








The drug product, FUZEON (enfuvirtide) for Injection, is a white to off-white,
sterile, lyophilized powder. Each single-use vial contains 108 mg of enfuvirtide
for the delivery of 90 mg. Prior to subcutaneous administration, the contents
of the vial are reconstituted with 1.1 mL of Sterile Water for Injection giving
a volume of approximately 1.2 mL to provide the delivery of 1 mL of the solution.
Each 1 mL of the reconstituted solution contains approximately 90 mg of enfuvirtide
with approximate amounts of the following excipients: 22.55 mg of mannitol,
2.39 mg of sodium carbonate (anhydrous), and sodium hydroxide and hydrochloric
acid for pH adjustment as needed. The reconstituted solution has an approximate
pH of 9.0.Last reviewed on RxList: 1/15/2010




Fuzeon Drug Description
FUZEON®
(enfuvirtide) for Injection
DRUG DESCRIPTION



What are the possible side effects of enfuvirtide (Fuzeon)?

Get emergency medical help if you have any of these signs of an allergic reaction: skin rash or hives; fever, chills; nausea, vomiting; difficulty breathing; feeling light-headed or fainting; swelling of your face, lips, tongue, or throat.
Stop using enfuvirtide and call your doctor at once if you have any of these serious side effects:

cough with fever, chest congestion, and shortness of breath;
signs of a new infection, such as fever or chills, cough, or flu symptoms.
...
Read All Potential Side Effects for Fuzeon »




FUZEON (enfuvirtide) is an inhibitor of the fusion of HIV-1 with CD4 cells.
Enfuvirtide is a linear 36-amino acid synthetic peptide with the N-terminus
acetylated and the C-terminus is a carboxamide. It is composed of naturally
occurring L-amino acid residues.
Enfuvirtide is a white to off-white amorphous solid. It has negligible solubility
in pure water and the solubility increases in aqueous buffers (pH 7.5) to 85-142
g/100 mL. The empirical formula of enfuvirtide is C204H301N51O64,
and the molecular weight is 4492. It has the following primary amino acid sequence:
CH3CO-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-LeuLeu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2
and the following structural formula:








The drug product, FUZEON (enfuvirtide) for Injection, is a white to off-white,
sterile, lyophilized powder. Each single-use vial contains 108 mg of enfuvirtide
for the delivery of 90 mg. Prior to subcutaneous administration, the contents
of the vial are reconstituted with 1.1 mL of Sterile Water for Injection giving
a volume of approximately 1.2 mL to provide the delivery of 1 mL of the solution.
Each 1 mL of the reconstituted solution contains approximately 90 mg of enfuvirtide
with approximate amounts of the following excipients: 22.55 mg of mannitol,
2.39 mg of sodium carbonate (anhydrous), and sodium hydroxide and hydrochloric
acid for pH adjustment as needed. The reconstituted solution has an approximate
pH of 9.0.Last reviewed on RxList: 1/15/2010




Fuzeon Drug Description
FUZEON®
(enfuvirtide) for Injection
DRUG DESCRIPTION



What are the possible side effects of enfuvirtide (Fuzeon)?

Get emergency medical help if you have any of these signs of an allergic reaction: skin rash or hives; fever, chills; nausea, vomiting; difficulty breathing; feeling light-headed or fainting; swelling of your face, lips, tongue, or throat.
Stop using enfuvirtide and call your doctor at once if you have any of these serious side effects:

cough with fever, chest congestion, and shortness of breath;
signs of a new infection, such as fever or chills, cough, or flu symptoms.
...
Read All Potential Side Effects for Fuzeon »




FUZEON (enfuvirtide) is an inhibitor of the fusion of HIV-1 with CD4 cells.
Enfuvirtide is a linear 36-amino acid synthetic peptide with the N-terminus
acetylated and the C-terminus is a carboxamide. It is composed of naturally
occurring L-amino acid residues.
Enfuvirtide is a white to off-white amorphous solid. It has negligible solubility
in pure water and the solubility increases in aqueous buffers (pH 7.5) to 85-142
g/100 mL. The empirical formula of enfuvirtide is C204H301N51O64,
and the molecular weight is 4492. It has the following primary amino acid sequence:
CH3CO-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-LeuLeu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2
and the following structural formula:








The drug product, FUZEON (enfuvirtide) for Injection, is a white to off-white,
sterile, lyophilized powder. Each single-use vial contains 108 mg of enfuvirtide
for the delivery of 90 mg. Prior to subcutaneous administration, the contents
of the vial are reconstituted with 1.1 mL of Sterile Water for Injection giving
a volume of approximately 1.2 mL to provide the delivery of 1 mL of the solution.
Each 1 mL of the reconstituted solution contains approximately 90 mg of enfuvirtide
with approximate amounts of the following excipients: 22.55 mg of mannitol,
2.39 mg of sodium carbonate (anhydrous), and sodium hydroxide and hydrochloric
acid for pH adjustment as needed. The reconstituted solution has an approximate
pH of 9.0.Last reviewed on RxList: 1/15/2010




Fuzeon Drug Description
FUZEON®
(enfuvirtide) for Injection
DRUG DESCRIPTION



What are the possible side effects of enfuvirtide (Fuzeon)?

Get emergency medical help if you have any of these signs of an allergic reaction: skin rash or hives; fever, chills; nausea, vomiting; difficulty breathing; feeling light-headed or fainting; swelling of your face, lips, tongue, or throat.
Stop using enfuvirtide and call your doctor at once if you have any of these serious side effects:

cough with fever, chest congestion, and shortness of breath;
signs of a new infection, such as fever or chills, cough, or flu symptoms.
...
Read All Potential Side Effects for Fuzeon »




FUZEON (enfuvirtide) is an inhibitor of the fusion of HIV-1 with CD4 cells.
Enfuvirtide is a linear 36-amino acid synthetic peptide with the N-terminus
acetylated and the C-terminus is a carboxamide. It is composed of naturally
occurring L-amino acid residues.
Enfuvirtide is a white to off-white amorphous solid. It has negligible solubility
in pure water and the solubility increases in aqueous buffers (pH 7.5) to 85-142
g/100 mL. The empirical formula of enfuvirtide is C204H301N51O64,
and the molecular weight is 4492. It has the following primary amino acid sequence:
CH3CO-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-LeuLeu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2
and the following structural formula:








The drug product, FUZEON (enfuvirtide) for Injection, is a white to off-white,
sterile, lyophilized powder. Each single-use vial contains 108 mg of enfuvirtide
for the delivery of 90 mg. Prior to subcutaneous administration, the contents
of the vial are reconstituted with 1.1 mL of Sterile Water for Injection giving
a volume of approximately 1.2 mL to provide the delivery of 1 mL of the solution.
Each 1 mL of the reconstituted solution contains approximately 90 mg of enfuvirtide
with approximate amounts of the following excipients: 22.55 mg of mannitol,
2.39 mg of sodium carbonate (anhydrous), and sodium hydroxide and hydrochloric
acid for pH adjustment as needed. The reconstituted solution has an approximate
pH of 9.0.Last reviewed on RxList: 1/15/2010





Other reviews about Enfuvirtide on wordpress

Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials.
  by JOC
Source: JAIDS Journal of Acquired Immune Deficiency Syndromes. 40(4):404-412, December 1, 2005. Nelson, Mark MA, MBBS, MRCP *; Arasteh, Keikawus MD +; Clotet, Bonaventura MD, PhD ++; Cooper, David […]


Safety of Enfuvirtide in Combination With an Optimized Background of Antiretrovirals in Treatment-Experienced HIV-1-Infected Adults Over 48 Weeks.
  by JOC
Source: JAIDS Journal of Acquired Immune Deficiency Syndromes. 40(4):413-421, December 1, 2005. Trottier, Benoit MD *; Walmsley, Sharon MD +; Reynes, Jacques MD, PhD ++; Piliero, Peter MD [S]; […]


New AIDS medication ready for clinical trial
  by huehueteotl
Raltegravir (MK-0518) and Maraviroc ready for clinical trials. LOS ANGELES, Feb. 28 - UPI reports that two new drugs appear to give patients who are running out […]


Phase 3 Results of Two Key Trials of Maraviroc, the First-in-Class CCR5 Antagonist
  by pozlife
  Coverage provided by Graeme Moyle, M.D. February 27, 2007 Maraviroc (MVC, UK-427,857) is the first CCR5 antagonist and the first oral agent with a new mechanism […]


Potent Peptides Inhibit HIV Entry Into Cells
  by huehueteotl
Based in part on protein structures determined at the National Synchrotron Light Source (NSLS) at the U.S. Department of Energy's Brookhaven National Laboratory, scientists at the University of […]


WHAT HIV DRUGS DO
  by Henry Bauer
The previous post (OFFICIAL GUIDELINES FOR HIV TREATMENT, 14 December 2007) offered some extracts from the text of the official Guidelines for treating “HIV-1 infected” people, even when […]


Treatment & Prevention
  by natsgi
  TREATMENT   When AIDS first surfaced in the United States, there were no drugs to combat the underlying immune deficiency and […]


Milestones in HIV
  by pozlife
Where we’ve been, where we’re going... photo: Bob Riha Jr MORE INFOStatistics from the Centers for Disease Control 1981 - […]


Routine “HIV” tests; herbal magic; Canadian natives at risk
  by Henry Bauer
“Veterans to routinely be offered HIV tests [posted 2009:08:19] --- The Veterans Affairs Department has begun offering routine HIV tests to veterans who receive medical care. The new […]


After a Month of Research...
  by carloscastrodad
Hey! this is my second post in my blog as part of the BioMINDS Program. First, I am going to give you some information about basic concepts of […]



Other reviews about Enfuvirtide on web:

Enfuvirtide is an HIV fusion inhibitor, the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. Enfuvirtide - Wikipedia, the free encyclopedia


Brand Name: Fuzeon: Other Name(s): DP 178, DP178, Enfuvirtida, Pentafuside, T 20, T-20, T20: Drug Class: Entry and Fusion Inhibitors: Drug Description AIDSinfo - HIV/AIDS Drug Information - Enfuvirtide


Enfuvirtide Brand names: Fuzeon® Chemical formula: Drug Forms: Enfuvirtide injection (below) Enfuvirtide Solution for injection Español: Enfuvirtide: Information from Answers.com


Brand Name: Fuzeon: Other Name(s): DP 178, DP178, Enfuvirtida, Pentafuside, T 20, T-20, T20: Drug Class: Entry and Fusion Inhibitors: Enfuvirtide, also known as Fuzeon or T-20, is a type ... AIDSinfo - HIV/AIDS Drug Information - Enfuvirtide


Learn about the prescription medication Fuzeon (Enfuvirtide), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Fuzeon (Enfuvirtide) Drug Information: Uses, Side Effects, Drug ...


All about Enfuvirtide. View complete and up to date Enfuvirtide information - part of the Drugs.com trusted medication database. Enfuvirtide Facts and Comparisons at Drugs.com


Approval: Enfuvirtide was approved by the FDA in March 2003 for use in adults, and in children ages 6 and older, with advanced HIV infection. The first agent to be approved in the ... Enfuvirtide (Fuzeon)


FUZEON (enfuvirtide) in combination with other antiretroviral agents is indicated for the treatment of HIV-1 infection in treatment-experienced patients with evidence of HIV-1 ... FUZEON® :: Home Page


Enfuvirtide is typically prescribed to treat HIV infection and AIDS. This selection from the eMedTV Web site offers an overview on how enfuvirtide works, its potential side effects ... Enfuvirtide


Enfuvirtide is a prescription drug used for the treatment of HIV, the virus that causes AIDS. It belongs to a family of antiretroviral drugs called fusion inhibitors. It was the ... Enfuvirtide - Medpedia





Featured Reviews

Reviews Spectinomycin

Trobicin Drug Description Trobicin® (spectinomycin) for Injectable Suspension, USP To reduce the development of drug-resistant bacteria and maintain the effectiveness of TROBICIN Sterile Powder and other antibacterial drugs, TROBICIN...
Read More  |  Review This
Reviews Nystatin Cream

Nystatin Cream Drug Description Nystatin Cream, USP Nystatin Ointment, USP DRUG DESCRIPTION What are the possible side effects of nystatin topical (Mycostatin Topical, Nystop, Pedi-Dri)? Get emergency medical help if you have any...
Read More  |  Review This
Reviews Insoluble Prussian blue

Radiogardase Drug Description Radiogardase® Prussian Blue Insoluble Capsules For Oral Administration DRUG DESCRIPTION What are the possible side effects of Prussian blue (Radiogardase)? Get emergency medical help if you...
Read More  |  Review This
Reviews Imiglucerase

Cerezyme Drug Description Cerezyme® (imiglucerase) Injection DRUG DESCRIPTION What are the possible side effects of imiglucerase (Cerezyme)? Symptoms of allergic reactions including difficulty breathing; closing of the throat;...
Read More  |  Review This
Reviews Insulin Human

Velosulin Drug Description DRUG DESCRIPTION Velosulin® BR is a clear solution of insulin in a phosphate buffer. The concentration of this product is 100 units of insulin per milliliter. This human insulin is structurally identical...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....